A Prospective Phase II of Daratumumab in Previously Treated Systemic Light-Chain (AL) Amyloidosis: Updated Results
Murielle Roussel(Centre Hospitalier Universitaire de Limoges), Arnaud Jaccard(Centre Hospitalier Universitaire de Limoges), Lionel Karlin(Hôpital Lyon Sud), Pierre Morel(Institut für Gießereitechnik), David Lavergne, Margaret Macro(Hôpital Cochin), Bruno Royer(Centre Hospitalier Universitaire Amiens-Picardie), Giovanni Palladini(University of Pavia), Aurore Perrot(Institut universitaire du cancer de Toulouse Oncopole), Giampaolo Merlini(University of Pavia), Frank Bridoux(Université de Poitiers), Laurent Frenzel(Hôpital Necker-Enfants Malades), Anne‐Marie Stoppa(Institut Paoli-Calmettes), Véronique Dorvaux, Antoine Huart, Bertrand Arnulf(Université Paris Cité)
Cited by 6
Related Papers
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k